Revisiting Biotech Emergence:

Biotech looks attractive at current levels. Biotech powershare etf shows encouraging signs of turning. The group severely underperformed the rest of the market in 2006. It has been a difficult place to make money and poised for a turnaround.

Stock Specific: ABI – deeply oversold with a support level at $28.

Other names to consider: DNA- multi-month trading range behavior – but given the positive group bias worth a shot.

TECH – strong volume as price increases. Buyers stepping in , worth a look on pullbacks.